Privium Fund Management B.V. Purchases 2,420 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Privium Fund Management B.V. grew its position in shares of Twist Bioscience Co. (NASDAQ:TWST) by 53.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,950 shares of the company’s stock after purchasing an additional 2,420 shares during the period. Privium Fund Management B.V.’s holdings in Twist Bioscience were worth $314,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in TWST. Principal Financial Group Inc. boosted its position in shares of Twist Bioscience by 67.5% during the 3rd quarter. Principal Financial Group Inc. now owns 205,864 shares of the company’s stock valued at $9,301,000 after acquiring an additional 82,953 shares during the last quarter. Farther Finance Advisors LLC raised its stake in Twist Bioscience by 1,173.8% in the third quarter. Farther Finance Advisors LLC now owns 3,401 shares of the company’s stock valued at $154,000 after purchasing an additional 3,134 shares in the last quarter. New York State Common Retirement Fund raised its stake in Twist Bioscience by 1.8% in the third quarter. New York State Common Retirement Fund now owns 482,606 shares of the company’s stock valued at $21,804,000 after purchasing an additional 8,529 shares in the last quarter. SteelPeak Wealth LLC bought a new stake in Twist Bioscience during the third quarter valued at approximately $416,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Twist Bioscience by 64.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,268 shares of the company’s stock worth $509,000 after buying an additional 4,427 shares during the last quarter.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock opened at $45.40 on Friday. The company’s 50 day moving average price is $43.69 and its 200-day moving average price is $45.64. Twist Bioscience Co. has a 52-week low of $15.85 and a 52-week high of $60.90. The stock has a market capitalization of $2.66 billion, a price-to-earnings ratio of -11.88 and a beta of 1.78.

Wall Street Analyst Weigh In

TWST has been the subject of several research reports. Leerink Partners upped their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Barclays cut their price objective on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 5th. Robert W. Baird boosted their target price on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research report on Monday, August 5th. JPMorgan Chase & Co. increased their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research report on Monday, August 5th. Finally, Evercore ISI boosted their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $51.22.

Insiders Place Their Bets

In other news, CFO Adam Laponis sold 856 shares of the company’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total transaction of $35,789.36. Following the completion of the transaction, the chief financial officer now directly owns 73,397 shares of the company’s stock, valued at approximately $3,068,728.57. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CFO Adam Laponis sold 856 shares of the business’s stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $41.81, for a total transaction of $35,789.36. Following the transaction, the chief financial officer now owns 73,397 shares in the company, valued at $3,068,728.57. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Emily M. Leproust sold 14,334 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total value of $639,296.40. Following the completion of the sale, the chief executive officer now owns 589,552 shares of the company’s stock, valued at approximately $26,294,019.20. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 73,356 shares of company stock valued at $3,205,239 in the last quarter. Insiders own 3.92% of the company’s stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.